Draganov DI, La Du BN. Pharmacogenetics of paraoxonases: a brief review. Naunyn-
Schmiedebergs Arch Pharmacol 2004;369:78–88.
Edmondson DE, Mattevi A, Binda C, Li M, Hubalek F. Structure and mechanism of
monoamine oxidase. Curr Med Chem 2004;11:1983–1993.
Ekins S, de Groot MJ, Jones JP. Pharmacophore and three-dimensional quantitative
structure activity relationship methods for modeling cytochrome p450 active sites.
Drug Metab Dispos 2001;29:936–944.
Emoto C, Murase S, Iwasaki K. Approach to the prediction of the contribution of major
cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage.
Xenobiotica; the fate of foreign compounds in biological systems 2006;36:671–683.
Ghahramani P, Ellis SW, Lennard MS, Ramsay LE, Tucker GT. Cytochromes P450
mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol 1997;43:
137–144.
Goosen TC, Arimoto R, Gifford E, Ball SE, Hurst SI, Tugnait M, Hollenberg PF,
Williams JA. A computational model based on UGT1A inhibition in human liver
microsomes predicts the tacrolimus-mycophenolic acid metabolic drug interaction.
Drug Metab Rev 2003;35:58.
He M, Rettie AE, Neal J, Trager WF. Metabolism of sulfinpyrazone sulfide and
sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s.
Drug Metab Dispos 2001;29:701–711.
Hernandez D, Addou S, Lee D, Orengo C, Shephard EA, Phillips IR.
Trimethylaminuria and a human FMO3 mutation database. Hum Mutat
2003;22:209–213.
Hickman D, Wang JP, Wang Y, Unadkat JD. Evaluation of the selectivity ofin vitro
probes and suitability of organic solvents for the measurement of human cytochrome
P450 monooxygenase activities. Drug Metab Dispos 1998;26:207–215.
Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and
OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol
Exp Ther 2004;311:139–146.
Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME. Characterization of
CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.
Cancer Res 2000;60:1189–1192.
Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes
involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003;31:540–547.
Hyland R, Roe EG, Jones BC, Smith DA. Identification of the cytochrome P450
enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol
2001;51:239–248.
Ito K, Hallifax D, Obach RS, Houston JB. Impact of parallel pathways of drug
elimination and multiple cytochrome P450 involvement on drug-drug interactions:
CYP2D6 paradigm. Drug Metab Dispos 2005;33:837–844.
Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, Sugiyama Y. Quantitative prediction of
in vivodrug clearance and drug interactions fromin vitrodata on metabolism,
together with binding and transport. Annu Rev Pharmacol Toxicol 1998;38:
461– 499.
Iwasa T, Sano H, Sugiura A, Uchiyama N, Hara K, Okochi H, Nakagawa K, Yasumori
T, Ishizaki T. Anin vitrointerethnic comparison of monoamine oxidase activities
506 REACTION PHENOTYPING